Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2023

Earnings Per Share [Abstract]

Schedule of computation of basic and diluted net loss per share

The following table sets forth the computation of basic and diluted net loss per share for the year ended December 31, 2023 and the period from July 11, 2022 through December 31, 2022 (in thousands, except share and per share amounts):

	Year Ended December 31,			Period from July 11, 2022 through December 31,
	2023			2022
Numerator
Net loss	$	(135,447	)	$	(54,503	)
Less: Net loss attributable to noncontrolling interests		(99,979	)		(40,103	)
Net loss available to Class A ordinary shareholders of ProKidney Corp.,    basic and diluted	$	(35,468	)	$	(14,400	)
Denominator
Weighted average Class A ordinary shares or ProKidney Corp. outstanding,    basic and diluted		61,714,225			61,540,231
Net loss per Class A Unit
Net loss per Class A ordinary share of ProKidney Corp., basic and diluted	$	(0.57	)	$	(0.23	)

	As of December 31,		As of December 31,
	2023		2022
Antidilutive securities
ProKidney Corp. Class B ordinary shares		168,297,916		171,578,320
Unvested Restricted Stock Rights		3,565,753		8,369,796
Earnout Rights		17,500,000		17,500,000
Legacy SCS Restricted Share Units		–		50,000
Stock options granted under the 2022 Equity Incentive Plan		14,680,109		9,504,715